

## Supplementary Materials

### BURDEN OF GASTRIC CANCER ATTRIBUTABLE TO *HELICOBACTER PYLORI* IN 27 COUNTRIES FROM SEVEN GEOGRAPHIC REGIONS IN 2022

Giulia Collatuzzo<sup>1</sup>, Elton Dajti<sup>1</sup>, Matteo Secco<sup>2</sup>, Franco Bazzoli<sup>1</sup>, Paolo Boffetta<sup>1,3,4</sup>, Rocco Maurizio Zagari<sup>1,5</sup>.

<sup>1</sup> Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. <sup>2</sup> Gastroenterology and Digestive Endoscopy Unit, Michele e Pietro Ferrero Hospital, Verduno, Cuneo, Italy. <sup>3</sup> Stony Brook Cancer Center, Stony Brook University, Stony Brook, USA. <sup>4</sup> Department of Family, Population and Preventive Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, USA. <sup>5</sup> Gastroesophageal Disease Unit, IRCCS - Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.


#### Corresponding Author

Rocco Maurizio Zagari, MD, Gastroesophageal Disease Unit, IRCCS – Azienda Ospedaliero-Universitaria di Bologna. Department of Medical and Surgical Sciences, University of Bologna. Via Massarenti, 9. 40138 Bologna, Italy. Email: [roccomaurizio.zagari@unibo.it](mailto:roccomaurizio.zagari@unibo.it)

**Table S1.** Electronic search strategy (up to 1.01.2023).

Electronic database	Search string	Results, n.
PUBMED	((“HP” OR “Helicobacter Pylori” OR “H. Pylori” OR “Campylobacter pylori” OR “Helicobacter pylori” [MeSh Terms]) AND “prevalence”)	25094
EMBASE	((‘HP’ OR ‘Helicobacter pylori’ OR ‘H pylori’ OR ‘Campylobacter pylori’) AND ‘prevalence’)	10275

**Fig. S1.** Flow chart of systematic literature search.



**Table S2.** Characteristics of the studies included in the meta-analysis for *Helicobacter pylori* prevalence in the period 2000-2010.

Reference	Country	Region	Study period	Subjects, n.	Age range (years)	<i>H. pylori</i> positive subjects, n.	<i>H.pylori</i> prevalence %	95% Confidence Interval	<i>H. pylori</i> diagnosis
Aguemon, B. D. <sup>22</sup>	Benin	Africa	2003-2004	247	16-74	213	86.2	70.0-80.9	Serology
Dube, C. <sup>23</sup>	South Africa	Africa	2008	228	25 ->60	216	94.7	83.3-90.3	SAT
Santos, I. S. <sup>24</sup>	Brazil	Latin America	2006-2007	1001	18-45	708	70.7	67.9-73.6	UBT
Ferreccio, C. <sup>25</sup>	Chile	Latin America	2003	2615	>17	1951	74.6	72.9-76.2	Serology
Sasaki, T. <sup>26</sup>	Ecuador	Latin America	2007	90	21- 82	65	72.2	63.0-81.5	SAT
Sasaki T. <sup>27</sup>	Panama	Latin America	2007	74	21-82	40	54	42.7-65.4	SAT
Weill, F. X. <sup>28</sup>	Guadeloupe (France)	Latin America	2000	854	18-70	459	53.7	51,7-58,8	Serology
Cardenas, V. M. <sup>29</sup>	Mexico	Latin America	2004	288	>1	110	38.2	31.7-44.6	SAT
Alavi, S. M. <sup>30</sup>	Iran	Eastern Mediterranean	2004-2005	96	30-60	55	57.3	47.4-67.2	Serology
Farshad, S. <sup>31</sup>	Iran	Eastern Mediterranean	2005-2007	226	18-83	94	41.6	35.2-48.0	RUT
Jafarzadeh, A. <sup>32</sup>	Iran	Eastern Mediterranean	2004	138	17-60	101	73.2	65.8-80.6	Serology
Jafarzadeh, A. <sup>33</sup>	Iran	Eastern Mediterranean	2005	200	20-60	135	67.5	61.0-74.0	Serology
Nourai, M. <sup>34</sup>	Iran	Eastern Mediterranean	2005	2326	18-65	1605	69	67.1-70.9	Serology

Mansour, K. B. <sup>35</sup>	Tunisia	Eastern Mediterranean	2006-2007	250	25-55	158	63.2	57.2-69.2	Serology
Katsanos, K. H. <sup>36</sup>	Albania	Europe	2005-2008	101	20 – 50	54	53.5	43.7-63.2	Histology
Katsanos, K. H. <sup>36</sup>	Greece	Europe	2005-2008	101	20-50	34	33.7	24.5-42.9	Histology
Bures, J et al. <sup>37</sup>	Czech Republic	Europe	2001	2509	5-100	1046	41.7	39.8-43.6	UBT
Kornerup L.S. <sup>38</sup>	Denmark	Europe	2002 - 2012	53633	>18	10552	19.7	19.3-20.0	UBT
Holleczeck B. <sup>39</sup>	Germany	Europe	2000-2002	9940	>18	4708	47.4	46.4-48.3	Serology
Loffeld L. J. R. F. <sup>40</sup>	Netherland	Europe	1993-2002	8190	4-99	3201	39.1	38.0-40.1	Histology
Van Blanckestein M. <sup>41</sup>	Netherland	Europe	2005	1551	17-80	491	31.7	29.4-34.0	Serology
Asfeldt, A. M. <sup>42</sup>	Norway	Europe	2004	916	18-85	348	38	34.9-41.1	Histology
Breckan, R. K. <sup>43</sup>	Norway	Europe	2004-2005	1736	18-85	368	21.2	19.3-23.1	SAT
Celinski, K. <sup>44</sup>	Poland	Europe	2000-2003	585	19-89	402	68.7	65.0-72.5	Serology
Baena Diez, J. M. <sup>45</sup>	Spain	Europe	1999-2001	208	>20	133	63.9	46.4-58.4	Serology
Sanchez Ceballos F. <sup>46</sup>	Spain	Europe	2004-2006	481	4-82	290	60.3	55.9-64.7	UBT
Cardenas, V. M. <sup>47</sup>	USA	North America	1999–2000	7462	3-70	2022	27.1	26.1-28.1	Serology
Ang, T. L. <sup>48</sup>	Thailand	South-East Asian	2007–2008	179	40-80	78	43.6	36.3-50.8	SAT
Moujaber, T. <sup>49</sup>	Australia	Western Pacific	2002	1811	>15	325	17.9	13.7-16.6	Serology
Windsor, H. M. <sup>50</sup>	Australia	Western Pacific	2003-2004	520	2-90	395	76	72.3-79.6	UBT
Chen, J. <sup>51</sup>	China	Western Pacific	2003	1006	20-92	565	56.2	44.5-49.6	Serology

Cheng, H. <sup>52</sup>	China	Western Pacific	2003	1232	2-79	577	46.8	44.0-49.5	UBT
Shi, R. <sup>53</sup>	China	Western Pacific	2004 – 2005	1371	5-100	851	62.1	59.5-64.6	Serology, UBT
Zhang, D. H. <sup>54</sup>	China	Western Pacific	2006	503	40-79	208	41.4	37.1-45.7	SAT
Zhang, D. H. <sup>54</sup>	China	Western Pacific	2006	526	40 -79	268	51	46.7-55.2	Histology
Fujimoto, Y. <sup>55</sup>	Japan	Western Pacific	2002	3819	17-84	2116	55.4	46.2-58.9	Serology
Hirai, I. <sup>56</sup>	Japan	Western Pacific	2007	186	40 -63	75	40.3	33.3-47.4	SAT
Kim, N. <sup>57</sup>	Korea	Western Pacific	2006	20154	16 ->70	12173	60.4	59.7-61.1	Serology, histology
Sung.K.C. <sup>58</sup>	Korea	Western Pacific	2001 – 2002	58981	30 - >60	41818	70.9	70.5-71.3	Serology, SAT, histology
Yim, J.Y. <sup>59</sup>	Korea	Western Pacific	2005	8020	≥20	4780	59.6	58.5-60.74	Serology
Sasidharan, S. <sup>60</sup>	Malaysia	Western Pacific	2000-2002	5370	10-70	763	14.2	13.2-15.1	Serology
Lin, Y. L. <sup>61</sup>	Taiwan	Western Pacific	2004 – 2006	9311	> 40	3650	39.2	38.3-40.2	RUT

*H. pylori*: *Helicobacter pylori*; CI: confidence interval; SAT: stool antigen test; UBT: urea breath test; RUT: rapid urease test.

**Table S3.** Quality assessment of selected studies.

Author (reference)	Representativeness of the cases*
Aguemon B.D. <sup>22</sup>	B
Dube C. <sup>23</sup>	B
Santos I.S. <sup>24</sup>	B
Ferreccio C. <sup>25</sup>	A
Sasaki T. <sup>26</sup>	B
Sasaki T. <sup>27</sup>	B
Weill F. <sup>28</sup>	B
Cardenas V.M. <sup>29</sup>	B
Alavi S.M. <sup>30</sup>	B
Farshad S. <sup>31</sup>	B
Jafarzadeh A. <sup>32</sup>	B
Jafarzadeh A. <sup>33</sup>	B
Nouraiie M. <sup>34</sup>	B
Mansour K.B. <sup>35</sup>	B
Katsanos K.H. <sup>36</sup>	B
Bures J. <sup>37</sup>	A
Kornerup L.S. <sup>38</sup>	B
Holleczeck B. <sup>39</sup>	B
Loffeld R.J.L.F. <sup>40</sup>	B
van Blankenstein M. <sup>41</sup>	B
Asfeldt A.M. <sup>42</sup>	A
Breckan R.K. <sup>43</sup>	A
Celinsky K. <sup>44</sup>	B
Baena Diez J.M. <sup>45</sup>	B
Sanchez Ceballos F. <sup>46</sup>	B
Cardenas V.M. <sup>47</sup>	A
Ang T.L. <sup>48</sup>	A
Moujaber T. <sup>49</sup>	B
Windsor H.M. <sup>50</sup>	B
Chen J. <sup>51</sup>	B
Cheng H. <sup>52</sup>	B
Shi R. <sup>53</sup>	B
Zhang D.H. <sup>54</sup>	B
Fujimoto Y. <sup>55</sup>	B
Hirai I. <sup>56</sup>	B
Kim N. <sup>57</sup>	B
Sung K.C. <sup>58</sup>	B
Yim J.Y. <sup>59</sup>	B
Sasidharan S. <sup>60</sup>	B
Lin Y.I. <sup>61</sup>	B

\*Representativeness of the cases:

A: Truly representative of the average prevalence of *Helicobacter pylori* infection in the community.

B: Somewhat representative of the average prevalence of *Helicobacter pylori* infection in the community.

C: Selected group of users; e.g. nurses, volunteers.

D: No description of the derivation of the cohort.

**Fig. S2.** Forest plot of the prevalence of *Helicobacter pylori* in the general population in 2000-2010 by country.

